X4 Pharmaceuticals (XFOR) Gross Profit (2024 - 2025)

X4 Pharmaceuticals (XFOR) posted Gross Profit of $2.2 million for Q4 2025, up 55.87% on a QoQ basis from $1.4 million in Q3 2025, and up 94.7% year-over-year from $1.1 million in Q4 2024.

X4 Pharmaceuticals (XFOR) Gross Profit (2024 - 2025) Analysis & Trends

X4 Pharmaceuticals' Gross Profit history runs 2 years deep, the most recent figure standing at $2.2 million for Q4 2025.

  • Quarterly Gross Profit rose 94.7% year-over-year to $2.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $29.4 million (up 1567.95% YoY) and the FY2025 annual result came in at $29.4 million, up 1567.95% from the prior year.
  • Gross Profit was $2.2 million for Q4 2025 at X4 Pharmaceuticals, up from $1.4 million in the prior quarter.
  • Across five years, Gross Profit topped out at $24.1 million in Q1 2025 and bottomed at $295000.0 in Q2 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 65,899.61 Bn 65,899.33 Bn -
2 Nanobiotix 1,933.82 Bn 1,933.76 Bn -
3 Akari Therapeutics 959.56 Bn 959.56 Bn -
4 BeOne Medicines 471.67 Bn 466.88 Bn 1.35 Bn
5 Vertex Pharmaceuticals 122.32 Bn 115.07 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.04 Bn 61.29 Bn 3.31 Bn
7 Belite Bio 62.06 Bn 62.06 Bn -
8 Argenx Se 55.93 Bn 50.74 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.55 Bn 34.54 Bn 959.66 Mn
10 X4 Pharmaceuticals 166.21 Mn -50.84 Mn 2.20 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 2.20 Mn
Dec 31, 2025 2.20 Mn
Sep 30, 2025 1.41 Mn
Sep 30, 2025 1.41 Mn
Jun 30, 2025 1.65 Mn
Jun 30, 2025 1.65 Mn
Mar 31, 2025 24.09 Mn
Mar 31, 2025 24.09 Mn
Dec 31, 2024 1.13 Mn
Dec 31, 2024 1.13 Mn
Sep 30, 2024 333,000.00
Sep 30, 2024 333,000.00
Jun 30, 2024 295,000.00
Jun 30, 2024 295,000.00